Mannkind Corporation Receivables Turnover Ratio (MNKD), from the third quarter 2026 to the third quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Mannkind Corporation  (NASDAQ: MNKD)
 

Mannkind Accounts Receivables Turnover Ratio from the third quarter 2026 to the third quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Mannkind Corporation's ability to collect accounts receivable sequentially worsen to 10.97, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Mannkind's Accounts Receivable average collection period in the Sep 30 2026 quarter, has increased to 33 days, from 29 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 250 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2026 from 686 to 1815.

What is Receivable Turnover Ratio?
What is Mannkind Corporation Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNKD Receivables Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Receivable Change 136.06 % 59.19 % -2.64 % 225.03 % -4.4 %
Y / Y Revenue Change 24.04 % 42.92 % 15.08 % 45.82 % 17.2 %
Receivable Turnover Ratio (TTM) 10.97 12.39 13 12.49 14.73
MNKD's Total Ranking # 1815 # 686 # 787 # 1366 #
Accounts Receivable average collection period days 33 29 28 29 25
Seq. Receivable Change -5.03 % 53.56 % -26.66 % 120.72 % -35.96 %
Seq. Revenue Change -6.86 % 21.3 % -19.46 % 36.31 % 7.32 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 251
Overall Market # 1815

Receivable Turnover Ratio Statistics
High Average Low
1.96 0.53 0.15
(Jun 30 2017)   (Dec 31 2017)




  News about Mannkind Corporation Receivables Turnover Ratios

MannKind Corporation Advances in Pulmonary Fibrotic Disease Treatment and Shows Stronger Financial Health

MannKind Corporation Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases MannKind Corporation has announced a significant milestone with the successful completion of a Phase 1 clinical trial for its innovative dry powder inhaler (DPI) formulation of nintedanib, targeted at treating pulmonary fibrotic diseases. This breakthrough in the company s product pipeline holds promise for patients suffering from conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases, where current treatment options are limited.The Phase 1 trial was designed to assess the safety, tolerability, and pharmacokinetics of nintedanib DPI, and the results have shown positive outcomes, reinforcing MannKind s commitment to addressing unmet medical needs in the respiratory space. Nintedanib, a well-characterized tyrosine kinase inhibitor, has previously been approved in oral formulation for treating IPF, but this novel delivery method aims to enhance patient adherence and improve bioavailability.


MNKD Company Profile • Back to MNKD Efficiency Comparisons • Compare MNKD Receivables Turnover Ratio to its Competitors

Financial Statements
Mannkind's Accounts Receivable $ 41 Millions Visit MNKD's Balance sheet
Mannkind's Sales TTM $ 413 Millions Visit MNKD's Income Statement
Sources of MNKD's Revenues Visit MNKD's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
MNKD's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
MNKD's Growth Rates MNKD's Roa MNKD's Inventory Turnover Ratio MNKD's Dividend Comparisons
MNKD's Profitability Ratios MNKD's Roi MNKD's Asset Turnover Ratio MNKD's Dividend Growth
MNKD's Valuation Ratios MNKD's Roe MNKD's Financial Strength Ratios MNKD's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Receivable at quarter ending Sep 30 2026
Sonida Senior Living Inc   27.65 $ 638.130  Millions$ 23.076  Millions
Wave Life Sciences Ltd   24.65 $ 87.296  Millions$ 3.541  Millions
Lenz Therapeutics Inc   24.39 $ 12.359  Millions$ 0.507  Millions
Arvinas Inc   20.06 $ 275.300  Millions$ 13.725  Millions
U S Physical Therapy Inc  18.16 $ 837.629  Millions$ 46.137  Millions
Alpha Pro Tech Ltd   17.54 $ 64.940  Millions$ 3.702  Millions
Biogen Inc   15.19 $ 10,297.300  Millions$ 677.900  Millions
Lifestance Health Group Inc   14.89 $ 1,676.889  Millions$ 112.631  Millions
Amneal Pharmaceuticals Inc   14.24 $ 3,196.184  Millions$ 224.488  Millions
Corcept Therapeutics Inc  13.44 $ 963.647  Millions$ 71.710  Millions
Precipio inc   13.38 $ 27.762  Millions$ 2.075  Millions
Chemed Corporation  12.65 $ 2,661.041  Millions$ 210.387  Millions
Caredx Inc   11.75 $ 497.396  Millions$ 42.330  Millions
Teladoc Health Inc   11.50 $ 2,468.143  Millions$ 214.604  Millions
Biodesix Inc   11.45 $ 105.212  Millions$ 9.192  Millions
Gossamer Bio Inc   11.37 $ 78.423  Millions$ 6.896  Millions
Icu Medical Inc  11.32 $ 2,183.556  Millions$ 192.845  Millions
Mannkind Corporation  10.97 $ 413.370  Millions$ 37.686  Millions
Lensar Inc   10.64 $ 60.079  Millions$ 5.645  Millions
Iqvia Holdings Inc   10.43 $ 17,311.000  Millions$ 1,659.500  Millions
Voyager Therapeutics Inc   9.84 $ 25.108  Millions$ 2.551  Millions
Myomo Inc   9.66 $ 47.775  Millions$ 4.947  Millions
Encompass Health Corporation  9.41 $ 6,338.100  Millions$ 673.625  Millions
Bausch Health Companies Inc   9.15 $ 11,113.000  Millions$ 1,215.000  Millions
Co diagnostics Inc   9.12 $ 0.859  Millions$ 0.094  Millions
Pacs Group Inc   8.88 $ 5,705.049  Millions$ 642.729  Millions
Lexicon Pharmaceuticals Inc   8.77 $ 38.537  Millions$ 4.396  Millions
Axogen inc   8.71 $ 266.926  Millions$ 30.654  Millions
Avita Medical Inc   8.65 $ 84.683  Millions$ 9.795  Millions
Ensign Group Inc  8.62 $ 5,674.305  Millions$ 658.477  Millions

Date modified: 2026-11-09T06:43:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.